Study detail
RecruitingPhase 1
An Open-Label Biomarker Study of BHV-1400 in IgA Nephropathy
Biohaven Therapeutics Ltd.
Summary
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
Eligibility
- Age range
- 18–65 years
- Sex
- All
- Healthy volunteers
- No
Detailed criteria
Key Inclusion Criteria: 1\. Participants must have biopsy-confirmed IgA Nephropathy Key Exclusion Criteria: 1. Any secondary IgAN 2. Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause